Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1996, for Schering-Plough Corporation. The company operates primarily in pharmaceutical products and health care products. The filing notes that the company is subject to competitive pricing pressures from managed care groups and government-mandated cost containment programs globally.
Key Financial Metrics
| Metric | Q1 1996 | Q1 1995 |
|---|---|---|
| Sales | $1,382.7 million | $1,224.2 million |
| Net Income | $326.6 million | $278.6 million |
| Earnings Per Share (Diluted) | $0.89 | $0.75 |
| Operating Cash Flow | $282.9 million | $106.7 million |
| Cash and Equivalents (End of Period) | $356.8 million | $126.2 million |
| Total Debt (Short-term + Long-term) | $820.7 million | $928.4 million |
| Cost of Sales Margin | 19.0% | 19.3% |
| Effective Tax Rate | 24.5% | 24.5% |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated sales increased 13% ($158.5 million) year-over-year. Excluding foreign currency effects, organic growth was 12%.
- Profitability: Income before taxes rose 15% to $432.6 million. Net income increased 17% to $326.6 million.
- Segment Performance:
- Pharmaceuticals: Sales grew 16% to $1,197.9 million. Domestic prescription sales surged 29%, driven by respiratory products (CLARITIN, VANCERIL) and anti-infectives (CEDAX, INTRON A).
- Health Care Products: Sales declined 5% to $184.8 million, primarily due to a 17% drop in over-the-counter products from private-label competition.
- Animal Health: Worldwide sales declined 7% (excluding currency) due to unfavorable market conditions for food-producing animals in the U.S.
- Debt Reduction: Short-term borrowings decreased by $106.5 million during the quarter.
- Share Repurchases: The company's $500 million share repurchase program was approximately 96% complete as of March 31, 1996.
Outlook, Risks, and Management Commentary
- Dividend Increase: In April 1996, the Board increased the quarterly dividend by 14% to $0.33 per share.
- Legal Proceedings (Antitrust): The company is a defendant in over 150 antitrust actions regarding price discrimination. A proposed $22.1 million settlement for a federal class action was initially rejected by the court in April 1996 but was amended on May 6, 1996, with a fairness hearing scheduled for June 11, 1996. The FTC is also investigating potential price-fixing conspiracies.
- Legal Proceedings (Product Liability): Subsidiaries face approximately 390 lawsuits regarding synthetic estrogens with total claims exceeding $2 billion. Management believes material liability in excess of accrued amounts is remote.
- Competitive Risks: Generic competition is impacting sales of the PROVENTIL line of asthma products. While the company's generic subsidiary (Warrick) has offset some declines, future profitability for this line is expected to be negatively affected.
- Regulatory Environment: Management notes that future operations and cash flows are difficult to estimate due to unpredictable domestic and international health care initiatives and government-mandated price cuts.
Investor Verification Checklist
- Antitrust Settlement Status: Verify the outcome of the June 11, 1996, fairness hearing regarding the amended $22.1 million antitrust settlement.
- Generic Competition Impact: Monitor the long-term sales trajectory of the PROVENTIL line as generic metered-dose inhalers gain market share.
- Share Repurchase Completion: Confirm the final completion of the $500 million share buyback program.
- Product Launch Performance: Track the sustained growth of new products CEDAX and INTRON A which drove significant Q1 gains.
- Regulatory Pricing Pressures: Assess the impact of ongoing government cost-containment programs on international pharmaceutical margins.